更“阳光”更惠民！国家“团购”药品为就医减负 健康保障更加“可及+可靠”

Group 1 - The core viewpoint of the news is the successful conclusion of the 11th batch of national organized drug centralized procurement and national medical insurance negotiations, which included 55 drugs, promoting quality and affordable medications for patients [1][5] - The new procurement rules are designed to be more transparent and beneficial to the public, fostering healthy competition in the pharmaceutical industry [1][7] - The introduction of the commercial insurance innovative drug catalog allows for a broader range of high-value drugs to be reviewed, with 121 drugs included in this new category [1][3] Group 2 - The 11th batch of centralized procurement results were announced, with a focus on common medications, expected to be available to patients by February 2026 [5] - The procurement rules have been upgraded to better align with clinical needs and drug quality, encouraging companies to ensure supply while promoting competition [7][11] - Over 46,000 medical institutions participated in the reporting process, with 77% reporting based on brand names, ensuring continuity in patient medication and fostering competition [8] Group 3 - Since 2018, the government has utilized centralized procurement and medical insurance negotiations to adjust drug prices, alleviating the financial burden on insurance funds and patients while ensuring reasonable profits for companies [10] - The procurement goals have evolved beyond mere price adjustments to guiding the transformation and upgrading of the pharmaceutical industry, ensuring accessible and reliable health care for patients [10] - The improved procurement rules include a revival mechanism that allows high-quality companies to re-enter the competition through price reductions, emphasizing quality oversight throughout the product lifecycle [11]